# Exosens Prom (EXENS.PA)

Canonical: https://gigainvestors.com/s/EXENS.PA

Analysis as of: 2026-10-16T07:38:51.531Z. 

Listing currency: EUR. Reporting currency: EUR.

## Verdict

Not enough history yet

Quality tests for Buy: not passed (profit record: pass; earnings resilience is evidence only). Published buy qualification: no.

Share price: EUR 57.65 per share; close as of 2026-10-15.

## Checklist

### understandable: na

### moat: na

### economics: na

### management: na

### accounting: na

## Holders

## Price story

Up 172% since Jun 2024

Story as of 2026-10-16T10:01:28.479Z; price observation 2026-10-15.

## Owner memo

Memo as of 2026-10-16T08:06:05.509Z.

### How it makes money

Operates in aerospace & defense; annual sales are EUR 468.2 million.

- Source: https://filings.xbrl.org/969500R3AKTPEDO9EG76/2025-12-31/ESEF/FR/0/exens-2025-12-31-fr.json (filed 2026-10-16T07:38:51.531Z); FY2025: revenue 468187000; grossProfit 102200000; margin = grossProfit / revenue.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); EXENS.PA: Exosens, together with its subsidiaries, develops, manufactures, and sells electro-optical technologies in France, Europe, North America, Asia, and internationally. It operates in two segments, Amplification and Detection and Imaging. The company offers image intensifier tubes; cameras, sensors, modules and cores, and imaging systems and solutions, including UV missile warning solution, atmospheric sounder, and spectroradiometer; and detection and imaging products for ions and electrons, photons, and neutrons, as well as micro pore optics and components, such as phosphor screens, resistive glass products, microchannel plates, and electron generator arrays. It also provides bare and energy compensated Geiger- Müller tubes; gamma and neutron detectors; mineral insulated extensions; and silicon photodiodes, as well as methane airborne detection solutions. The company sells its products under the Exosens, Photonis, Xenics, Telops, El-Mul, and Noxant brand names. It serves defense and surveillance, life sciences and environment, industrial control, and nuclear markets. The company was founded in 1937 and is headquartered in Mérignac, France.

### Why customers stay

Margins ranged from 21.8% to 60.6% during 2023–25.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2023-12-31 (filed 2026-10-16T07:38:51.531Z); FY2023: grossProfit / revenue = 60.6%.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2024-12-31 (filed 2026-10-16T07:38:51.531Z); FY2024: grossProfit / revenue = 58.8%.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2025-12-31 (filed 2026-10-16T07:38:51.531Z); FY2025: grossProfit / revenue = 21.8%.

### Where the cash goes

Spends 25.9% of cash earnings on expansion; paid dividends in 1 of 6 years.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2022-12-31 (filed 2026-10-16T07:38:51.531Z); FY2022: growth capex 2809000; upkeep 18989000; owner earnings 9285200. Growth capex / owner earnings = 0.30252444750786195.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2023-12-31 (filed 2026-10-16T07:38:51.531Z); FY2023: growth capex 0; upkeep 30938000; owner earnings 19645400. Growth capex / owner earnings = 0.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2024-12-31 (filed 2026-10-16T07:38:51.531Z); FY2024: growth capex 3059000; upkeep 38200000; owner earnings 28500000. Growth capex / owner earnings = 0.10733333333333334.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2025-12-31 (filed 2026-10-16T07:38:51.531Z); FY2025: growth capex 10200000; upkeep 39900000; owner earnings 39395000. Growth capex / owner earnings = 0.2589161061048356.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16T07:38:51.531Z); Dividend observations: [[2020,0],[2021,0],[2022,0],[2023,0],[2024,0],[2025,5078000]]. Zero only counted when supported by a complete cash-flow statement.

- Source: https://eodhd.com/api/fundamentals/EXENS.PA.json#2025-12-31 (filed 2026-10-16T07:38:51.531Z); FY2025: cash repurchases 5600000 EUR.

### Are managers owners

Insiders own 31.3% of the company.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16); EXENS.PA SharesStats.PercentInsiders = 31.25 percentage points; cache date 2026-10-16.

### What the price says

The price is 6.2 times annual sales.

- Source: https://eodhd.com/financial-apis/stock-etfs-fundamental-data-feeds/ (filed 2026-10-16T07:38:51.531Z); Closing price 57.65 EUR; reporting-to-trading FX 1; FY2025 annual sales per share 9.236388308546232; price multiple 6.24161718565445. FY2025 cash earnings/share 0.7771841538000389. Closing-price date 2026-10-15.

## Monthly share-price history (EUR per share)

- 2024-06: EUR 21.21 per share

- 2024-07: EUR 21.00 per share

- 2024-08: EUR 20.25 per share

- 2024-09: EUR 20.20 per share

- 2024-10: EUR 19.40 per share

- 2024-11: EUR 18.20 per share

- 2024-12: EUR 19.43 per share

- 2025-01: EUR 22.89 per share

- 2025-02: EUR 25.98 per share

- 2025-03: EUR 33.83 per share

- 2025-04: EUR 34.35 per share

- 2025-05: EUR 43.35 per share

- 2025-06: EUR 40.35 per share

- 2025-07: EUR 40.90 per share

- 2025-08: EUR 39.30 per share

- 2025-09: EUR 43.20 per share

- 2025-10: EUR 48.85 per share

- 2025-11: EUR 41.95 per share

- 2025-12: EUR 48.45 per share

- 2026-01: EUR 53.90 per share

- 2026-02: EUR 62.30 per share

- 2026-03: EUR 61.20 per share

- 2026-04: EUR 64.85 per share

- 2026-05: EUR 68.15 per share

- 2026-06: EUR 57.10 per share

- 2026-07: EUR 57.20 per share

- 2026-08: EUR 58.05 per share

- 2026-09: EUR 59.80 per share

- 2026-10: EUR 57.00 per share

## Annual estimated value (EUR per share)

Historical values use today's bond yield for every fiscal year

Historical values use today's FX rate into trading currency for every fiscal year

Historical values use current restated fundamentals and current commodity classification; they are not point-in-time estimates

## Sources

Estimates depend on assumptions and are not guarantees or investment advice. Underlying data remains subject to its source licenses; public reading does not grant bulk redistribution rights.